These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16448328)

  • 1. Eszopiclone for the treatment of insomnia.
    Scharf M
    Expert Opin Pharmacother; 2006 Feb; 7(3):345-56. PubMed ID: 16448328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eszopiclone: a review of its use in the treatment of insomnia.
    Hair PI; McCormack PL; Curran MP
    Drugs; 2008; 68(10):1415-34. PubMed ID: 18578559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
    Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T
    Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
    Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
    Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polysomnography study of eszopiclone in elderly patients with insomnia.
    McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
    Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
    Scharf M; Erman M; Rosenberg R; Seiden D; McCall WV; Amato D; Wessel TC
    Sleep; 2005 Jun; 28(6):720-7. PubMed ID: 16477959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor.
    Drugs R D; 2005; 6(2):111-5. PubMed ID: 15777104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
    Zammit GK; McNabb LJ; Caron J; Amato DA; Roth T
    Curr Med Res Opin; 2004 Dec; 20(12):1979-91. PubMed ID: 15701215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
    Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
    Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eszopiclone for insomnia.
    Rösner S; Englbrecht C; Wehrle R; Hajak G; Soyka M
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010703. PubMed ID: 30303519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
    Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T
    Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eszopiclone for insomnia.
    Melton ST; Wood JM; Kirkwood CK
    Ann Pharmacother; 2005 Oct; 39(10):1659-66. PubMed ID: 16131537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
    Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
    Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
    Liang L; Huang Y; Xu R; Wei Y; Xiao L; Wang G
    Sleep Med; 2019 Oct; 62():6-13. PubMed ID: 31518944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
    Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
    Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.
    Krystal AD; Huang H; Zummo J; Grinnell T; Marshall RD
    Sleep Med; 2012 Jun; 13(6):691-6. PubMed ID: 22465450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eszopiclone for late-life insomnia.
    McCrae CS; Ross A; Stripling A; Dautovich ND
    Clin Interv Aging; 2007; 2(3):313-26. PubMed ID: 18044182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder.
    Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H
    Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study.
    Spierings EL; McAllister PJ; Bilchik TR
    Cranio; 2015 Apr; 33(2):115-21. PubMed ID: 25323219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.